View Prezista overdosage for action to be taken in the event of an overdose.
Administration
Should be taken with food.
Contraindications
Hypersensitivity. Not to be co-administered w/ drugs highly dependent on CYP3A clearance eg, alfuzosin, astemizole, cisapride, colchicine (in patients w/ renal &/or hepatic impairment), dapoxetine, dronedarone, elbasvir/grazoprevir, ergot alkaloids, ivabradine, lomitapide, lovastatin, lurasidone, PO midazolam, naloxegol, pimozide, ranolazine, sildenafil (for PAH), simvastatin, terfenadine, triazolam. Not to be used w/ potent CYP3A inducers-containing products eg, rifampin or St. John's wort.
Severe skin reactions, discontinue if signs & symptoms of severe skin reactions developed; sulfonamide allergy. Patients w/ hepatic impairment, hepatotoxicity, lab testing should be conducted prior & during treatment. Renal impairment. Hemophilia. Metabolic disorders, new onset DM, hyperglycemia, consider to measure fasting serum lipids & blood glucose; lipid disorders should be managed as clinically appropriate. Immune reconstitution inflammatory syndrome. Concomitant use w/ CYP3A-, CYP2D6-metabolized drugs or P-gp transported drugs; CYP3A inducers & inhibitors. May affect ability to drive or operate machinery. Pregnancy. Not to be used during lactation. Not to be used in childn <12 yr & adolescents 12-17 yr. Elderly ≥65 yr.
Sign Out
